Prognostic Significance of Severe Vitamin D Deficiency in Patients with Primary Sclerosing Cholangitis

被引:4
|
作者
Ebadi, Maryam [1 ]
Rider, Elora [1 ]
Tsai, Catherine [1 ]
Wang, Sarah [1 ]
Lytvyak, Ellina [1 ]
Mason, Andrew [1 ]
Montano-Loza, Aldo J. [1 ]
机构
[1] Univ Alberta Hosp, Div Gastroenterol, Liver Unit, Edmonton, AB T6G 2X8, Canada
基金
加拿大健康研究院;
关键词
chronic cholestasis; low levels of serum vitamin D; liver-related mortality; progression of cirrhosis; 25-HYDROXYVITAMIN D DEFICIENCY; NATURAL-HISTORY; POOR-PROGNOSIS; LIVER; SURVIVAL; DISEASE; RISK;
D O I
10.3390/nu15030576
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Vitamin D deficiency has been linked with adverse events in various liver diseases. The present study aimed to recognize the association between severe vitamin D deficiency and disease progression, hepatobiliary malignancies, liver-related mortality, and the need for liver transplantation in primary sclerosing cholangitis (PSC). Patients with a diagnosis of PSC (n = 354), followed by the autoimmune liver disease clinic at the University of Alberta, were included. Patients with vitamin D levels < 25 nmol/L were defined as severely deficient. Univariate and multivariate analyses were conducted using the Cox proportional hazards regression models. The mean vitamin D level was 59 +/- 2 nmol/L, and 63 patients (18%) had a severe vitamin D deficiency. Patients with a severe vitamin D deficiency were 2.5 times more likely to experience hepatobiliary malignancies (HR 2.55, 95% CI, 1.02-6.40, p = 0.046). A severe vitamin D deficiency at diagnosis (HR 1.82, 95% CI, 1.05-3.15, p = 0.03) and persistent deficiencies over time (HR 2.26, 95% CI, 1.17-4.37, p = 0.02) were independently associated with a higher risk of poor clinical liver outcomes. A severe vitamin D deficiency at diagnosis and persistent deficiency at longitudinal assessments were associated with liver-related mortality or the need for liver transplantation.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Fatigue in patients with primary sclerosing cholangitis
    Björnsson, E
    Simren, M
    Olsson, R
    Chapman, RW
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2004, 39 (10) : 961 - 968
  • [22] Natural history and prognostic models in primary sclerosing cholangitis
    Talwalkar, JA
    Lindor, KD
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2001, 15 (04) : 563 - 575
  • [23] Validation of a cholangiographic prognostic model in primary sclerosing cholangitis
    Ponsioen, C. Y.
    Reitsma, J. B.
    Boberg, K. M.
    Aabakken, L.
    Rauws, E. A. J.
    Schrumpf, E.
    ENDOSCOPY, 2010, 42 (09) : 742 - 747
  • [24] Pregnancy in patients with primary sclerosing cholangitis
    Janczewska, I
    Olsson, R
    Hultcrantz, R
    Broome, U
    LIVER, 1996, 16 (05): : 326 - 330
  • [25] Cholangiocarcinoma in patients with primary sclerosing cholangitis
    Fung, Brian M.
    Tabibian, James H.
    CURRENT OPINION IN GASTROENTEROLOGY, 2020, 36 (02) : 77 - 84
  • [26] Management of patients with primary sclerosing cholangitis
    Stiehl, A
    Benz, C
    Sauer, P
    BILE ACIDS IN HEPATOBILIARY DISEASE, 2000, 110B : 47 - 50
  • [27] ABNORMALITIES IN TESTS OF COPPER-METABOLISM IN PRIMARY SCLEROSING CHOLANGITIS - PROGNOSTIC AND DIAGNOSTIC-SIGNIFICANCE
    GROSS, JB
    BEAVER, SJ
    MCCALL, JT
    LUDWIG, J
    LARUSSO, NF
    GASTROENTEROLOGY, 1983, 84 (05) : 1176 - 1176
  • [28] SURVIVAL AND USE OF A PROGNOSTIC MODEL IN PRIMARY SCLEROSING CHOLANGITIS
    FARRANT, JM
    HAYLLAR, K
    LO, SK
    CHAPMAN, RW
    WILLIAMS, R
    GUT, 1991, 32 (10) : A1249 - A1250
  • [29] Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis
    Broome, U
    Olsson, R
    Loof, L
    Bodemar, G
    Hultcrantz, R
    Danielsson, A
    Prytz, H
    SandbergGertzen, H
    Wallerstedt, S
    Lindberg, G
    GUT, 1996, 38 (04) : 610 - 615
  • [30] Severe coagulopathy caused by rifampicin in patients with primary sclerosing cholangitis and refractory pruritus
    Sampaziotis, Fotios
    Griffiths, William J. H.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (05) : 826 - 827